Myriad Genetics Inc (MYGN) support and resistance · rev $837.6M
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
This page maps Myriad Genetics Inc (MYGN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
MYGN currently screens at market cap $413.7M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new MYGN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the MYGN quote page for the session range and the stock page for the full model.
Not investment advice.